ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Blackstone Life Sciences has pledged $250 million to form a company with Cellex Cell Professionals and Intellia Therapeutics to develop universal chimeric antigen receptor T-cell (CAR-T) therapies that can use donor cells instead of cells from a person with the disease being treated. The new firm will acquire the immunotherapy and cell therapy company GEMoaB from Cellex. GEMoaB is developing switchable CAR-T therapies intended to have increased safety and efficacy across several types of cancer. Intellia is a gene-editing company that uses CRISPR-Cas9 to develop therapies.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X